TY - JOUR
T1 - pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs
AU - Raghunand, Natarajan
AU - Martínez-Zaguilán, Raul
AU - Wright, Stephen H.
AU - Gillies, Robert J.
N1 - Funding Information:
This work was supported by the US Army Breast Cancer Research Program, Grant DAMD17–94-J-4368 (N.R, R.J.G.) and NIH DK49222 (S.H.W.).
PY - 1999/5/1
Y1 - 1999/5/1
N2 - Resistance to chemotherapeutic agents is a major cause of treatment failure in patients with cancer. The primary mechanism leading to a multidrug-resistant phenotype is assumed to be plasma-membrane localized overexpression of drug efflux transporters, such as P-glycoprotein (P-gp). However, acidic intracellular organelles can also participate in resistance to chemotherapeutic drugs. In this study, we investigated, both experimentally and theoretically, the effect of acidic vesicle turnover on drug resistance. We have developed a general model to account for multiple mechanisms of resistance to weakly basic organic cations, e.g. anthracyclines and Vinca alkaloids. The model predicts that lower cytosolic concentrations of drugs can be achieved through a combination of high endosomal turnover rates, a low endosomal pH, and an alkaline-inside pH gradient between cytosol and the extracellular fluid. Measured values for these parameters have been inserted into the model. Computations using conservative values of all parameters indicate that turnover of acidic vesicles can be an important contributor to the drug-resistant phenotype, especially if vesicles contain an active uptake system, such as H+/cation exchange. Even conservative estimates of organic cation-proton antiport activity would be sufficient to make endosomal drug extrusion a potent mechanism of resistance to weakly basic drugs. The effectiveness of such a drug export mechanism would be comparable to drug extrusion via drug pumps such as P-gp. Thus, turnover of acidic vesicles can be an important factor in chemoresistance, especially in cells that do not overexpress plasma membrane-bound drug pumps like P-glycoprotein. Copyright (C) 1999 Elsevier Science Inc.
AB - Resistance to chemotherapeutic agents is a major cause of treatment failure in patients with cancer. The primary mechanism leading to a multidrug-resistant phenotype is assumed to be plasma-membrane localized overexpression of drug efflux transporters, such as P-glycoprotein (P-gp). However, acidic intracellular organelles can also participate in resistance to chemotherapeutic drugs. In this study, we investigated, both experimentally and theoretically, the effect of acidic vesicle turnover on drug resistance. We have developed a general model to account for multiple mechanisms of resistance to weakly basic organic cations, e.g. anthracyclines and Vinca alkaloids. The model predicts that lower cytosolic concentrations of drugs can be achieved through a combination of high endosomal turnover rates, a low endosomal pH, and an alkaline-inside pH gradient between cytosol and the extracellular fluid. Measured values for these parameters have been inserted into the model. Computations using conservative values of all parameters indicate that turnover of acidic vesicles can be an important contributor to the drug-resistant phenotype, especially if vesicles contain an active uptake system, such as H+/cation exchange. Even conservative estimates of organic cation-proton antiport activity would be sufficient to make endosomal drug extrusion a potent mechanism of resistance to weakly basic drugs. The effectiveness of such a drug export mechanism would be comparable to drug extrusion via drug pumps such as P-gp. Thus, turnover of acidic vesicles can be an important factor in chemoresistance, especially in cells that do not overexpress plasma membrane-bound drug pumps like P-glycoprotein. Copyright (C) 1999 Elsevier Science Inc.
KW - Compartmentation
KW - Exocytosis
KW - Mathematical model
KW - Multidrug resistance
KW - Organic cation transport
KW - Vacuolar-type H-ATPase
UR - http://www.scopus.com/inward/record.url?scp=0345389967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345389967&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(99)00021-0
DO - 10.1016/S0006-2952(99)00021-0
M3 - Article
C2 - 10796075
AN - SCOPUS:0345389967
SN - 0006-2952
VL - 57
SP - 1047
EP - 1058
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 9
ER -